Compare Merck & Co., Inc. (MRK) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Merck & Co., Inc. trades at $145.83 (market cap $351.28B), while Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B). The key difference: Merck & Co., Inc. is far larger — about 5.4× Schwab US Large Cap Growth ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| MRK | SCHG | |
|---|---|---|
Market Cap | $351.28B | $65.01B |
Volume | 7,969,665 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $156.43 | $36.93 |
52-Week Low | $82.49 | $28.10 |
Typical Hold Time | 98 Days | 50 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
SCHG trades at $36.72, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's role in growth portfolios and tax-efficient strategies, with Seeking Alpha noting its valuation discount compared to QQQM as of September 9, 2026.
SCHG offers exposure to large-cap growth stocks with competitive fees, though concentration in top holdings presents both opportunity and risk. The ETF's performance is closely tied to megacap technology names, making it sensitive to sector rotations. Long-term growth potential remains supported by historical outperformance, but investors should monitor holding concentration and market leadership shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
